AR091237A1 - Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf) - Google Patents
Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf)Info
- Publication number
- AR091237A1 AR091237A1 ARP130101931A AR091237A1 AR 091237 A1 AR091237 A1 AR 091237A1 AR P130101931 A ARP130101931 A AR P130101931A AR 091237 A1 AR091237 A1 AR 091237A1
- Authority
- AR
- Argentina
- Prior art keywords
- growth
- compositions
- factor
- pdgf
- vegf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Composiciones que comprenden un aptámero anti factor de crecimiento derivado de plaqueta (anti-PDGF) y un antagonista de factor de crecimiento del endotelio vascular (VEGF). En algunas formas de realización, las composiciones de la presente son útiles para el tratamiento y prevención de enfermedades oftalmológicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261654672P | 2012-06-01 | 2012-06-01 | |
US201361778208P | 2013-03-12 | 2013-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR091237A1 true AR091237A1 (es) | 2015-01-21 |
Family
ID=49674074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101931 AR091237A1 (es) | 2012-06-01 | 2013-05-31 | Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf) |
Country Status (18)
Country | Link |
---|---|
US (1) | US20150182623A1 (es) |
EP (1) | EP2854844A4 (es) |
JP (1) | JP2015519373A (es) |
KR (1) | KR20150033620A (es) |
CN (1) | CN104619335A (es) |
AR (1) | AR091237A1 (es) |
AU (1) | AU2013267310A1 (es) |
CA (1) | CA2874412A1 (es) |
CL (1) | CL2014003233A1 (es) |
CO (1) | CO7240393A2 (es) |
EA (1) | EA201492289A1 (es) |
HK (1) | HK1207983A1 (es) |
IL (1) | IL235797A0 (es) |
MX (1) | MX2014014445A (es) |
PH (1) | PH12014502577A1 (es) |
SG (1) | SG11201407981RA (es) |
TW (1) | TW201400122A (es) |
WO (1) | WO2013181495A2 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2915255A1 (en) | 2013-07-12 | 2015-01-15 | Ophthotech Corporation | Methods for treating or preventing ophthalmological conditions |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
EP3194029A1 (en) * | 2014-08-11 | 2017-07-26 | Ophthotech Corporation | Methods for treating or preventing ophthalmological conditions |
CN105435221B (zh) * | 2014-09-22 | 2021-09-28 | 正大天晴药业集团股份有限公司 | 一种针对血管内皮生长因子的人源化抗体的药物组合物 |
WO2016120753A1 (en) | 2015-01-28 | 2016-08-04 | Pfizer Inc. | Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation |
CN105806830B (zh) * | 2015-12-10 | 2019-01-29 | 北京联众泰克科技有限公司 | 一种稳定的hrp酶促化学发光底物液、其制备方法及应用 |
SG11201805420SA (en) | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
WO2017129685A1 (en) | 2016-01-26 | 2017-08-03 | Formycon Ag | Liquid formulation of a vegf antagonist |
JP7081818B2 (ja) * | 2016-02-04 | 2022-06-07 | エーディーエス・セラピューティクス・エルエルシー | 疾患治療のための抗体-薬剤相乗作用技術 |
WO2017147293A1 (en) * | 2016-02-23 | 2017-08-31 | Eleven Biotherapeutics, Inc. | Il-6 antagonist formulations and uses thereof |
CN116327963A (zh) * | 2016-11-21 | 2023-06-27 | 济世-伊沃泰克生物制品有限公司 | 一种眼科制剂及其用途 |
KR101861163B1 (ko) * | 2017-04-26 | 2018-05-25 | 삼천당제약주식회사 | 안과용 약학 조성물 |
KR20200089282A (ko) * | 2017-11-20 | 2020-07-24 | 저스트-에보텍 바이오로직스, 아이엔씨. | 등장화제로서 라이신 염을 함유하는 아플리베르셉트 제제 및 그것의 용도 |
WO2019210097A1 (en) * | 2018-04-25 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Aptamers with stability, potency or half-life for enhanced safety and efficacy |
SG11202010684YA (en) | 2018-05-10 | 2020-11-27 | Regeneron Pharma | High concentration vegf receptor fusion protein containing formulations |
US20210353713A1 (en) * | 2018-10-26 | 2021-11-18 | Amgen Inc. | Formulations comprising a tris buffer and a protein |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
KR20210077645A (ko) * | 2019-12-17 | 2021-06-25 | 주식회사 프로젠 | 신규 주사제 제형 |
JP2023516377A (ja) * | 2020-03-04 | 2023-04-19 | 上海復宏漢霖生物技術股▲フン▼有限公司 | ベバシズマブを含む薬物製剤 |
KR20220013343A (ko) * | 2020-07-24 | 2022-02-04 | (주) 팬젠 | 안과용 액상 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2281885A1 (en) * | 2003-08-27 | 2011-02-09 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
SI2364691T1 (sl) * | 2006-06-16 | 2013-08-30 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
CA2760687A1 (en) * | 2009-05-01 | 2010-11-04 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
US9046513B2 (en) * | 2010-08-26 | 2015-06-02 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
-
2013
- 2013-05-31 WO PCT/US2013/043536 patent/WO2013181495A2/en active Application Filing
- 2013-05-31 MX MX2014014445A patent/MX2014014445A/es unknown
- 2013-05-31 CN CN201380035401.4A patent/CN104619335A/zh active Pending
- 2013-05-31 AR ARP130101931 patent/AR091237A1/es unknown
- 2013-05-31 JP JP2015515222A patent/JP2015519373A/ja active Pending
- 2013-05-31 EA EA201492289A patent/EA201492289A1/ru unknown
- 2013-05-31 SG SG11201407981RA patent/SG11201407981RA/en unknown
- 2013-05-31 EP EP13796692.5A patent/EP2854844A4/en not_active Withdrawn
- 2013-05-31 TW TW102119528A patent/TW201400122A/zh unknown
- 2013-05-31 AU AU2013267310A patent/AU2013267310A1/en not_active Abandoned
- 2013-05-31 KR KR20147036638A patent/KR20150033620A/ko not_active Application Discontinuation
- 2013-05-31 CA CA2874412A patent/CA2874412A1/en not_active Abandoned
-
2014
- 2014-11-19 PH PH12014502577A patent/PH12014502577A1/en unknown
- 2014-11-20 IL IL235797A patent/IL235797A0/en unknown
- 2014-11-26 US US14/554,894 patent/US20150182623A1/en not_active Abandoned
- 2014-11-27 CL CL2014003233A patent/CL2014003233A1/es unknown
- 2014-12-26 CO CO14284190A patent/CO7240393A2/es unknown
-
2015
- 2015-09-06 HK HK15108671.2A patent/HK1207983A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
KR20150033620A (ko) | 2015-04-01 |
SG11201407981RA (en) | 2015-01-29 |
CL2014003233A1 (es) | 2015-06-19 |
WO2013181495A3 (en) | 2014-02-13 |
EP2854844A2 (en) | 2015-04-08 |
AU2013267310A1 (en) | 2014-12-11 |
CN104619335A (zh) | 2015-05-13 |
WO2013181495A2 (en) | 2013-12-05 |
PH12014502577A1 (en) | 2015-01-21 |
EA201492289A1 (ru) | 2015-05-29 |
CA2874412A1 (en) | 2013-12-05 |
CO7240393A2 (es) | 2015-04-17 |
MX2014014445A (es) | 2015-08-14 |
IL235797A0 (en) | 2015-01-29 |
JP2015519373A (ja) | 2015-07-09 |
US20150182623A1 (en) | 2015-07-02 |
HK1207983A1 (en) | 2016-02-19 |
TW201400122A (zh) | 2014-01-01 |
EP2854844A4 (en) | 2016-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR091237A1 (es) | Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf) | |
CO2017004715A2 (es) | Métodos y formulaciones para tratar enfermedades vasculares de los ojos | |
CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
ECSP17018120A (es) | Triazolopirazinonas como inhibidores de pde1 | |
CL2015000061A1 (es) | Anticuerpos biespecíficos anti-vegf/anti-ang-2 y su utilización en el tratamiento de enfermedades vasculares oculares | |
CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
GT201600007A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
CR20150386A (es) | Composiciones de nanoparticulas de albumina y paclitaxel | |
CL2016000055A1 (es) | Métodos para tratar o prevenir afecciones oftalmológicas | |
UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
DOP2017000254A (es) | Imidazopirazinonas como inhibidores de pde1 | |
CO7020876A2 (es) | Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas | |
MX2015009058A (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
UY36171A (es) | Derivados heteroaromáticos bicíclicos fusionados como inhibidores de quinasa | |
CY1121787T1 (el) | Sirna και χρηση αυτων σε μεθοδους και συνθεσεις για τη θεραπεια ή/και προληψη οφθαλμικων καταστασεων | |
NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
CU20160151A7 (es) | 2-AMIN0-6-METI L-4,4a, 5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
CY1121000T1 (el) | Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων | |
CO2017011778A2 (es) | Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden | |
MX2017005975A (es) | Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso. | |
EP3060259A4 (en) | Methods of treating or preventing vascular diseases of the retina | |
ECSP16061208A (es) | Quinazolin-thf-aminas como inhibidores de pde1 | |
DOP2016000263A (es) | Quinazolin-thf-aminas halogenadas como inhibidores de pde1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |